Hematology | Page 2 | Pfizer Medical Information

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.

Back to Diseases Areas

Poster

Pennesi E, Brivio E, Ammerlaan ACJ, Jiang Y, Van Der Velden VHJ, Beverloo HB, Sleight B, Rives S, Diaz-de-Heredia Rubio C, Sirvent FJB, Rubio-San-Simón A, Rialland F, Rizzari C, Bielorai B, Petit A, Bruno B, Øra I, Nilsson A, Engstler G, Rossig C, Brethon B, Locatelli F, Zwaan CM December 12, 2022 ASH 2022 Hematology

Inotuzumab Ozogamicin (InO) Combined With UKALL-R3 Modified Chemotherapy in Pediatric Patients With B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) – Results From the ITCC-059 Phase 1B Trial

View Presentation

Poster

Landgren O, Kazandjian D, O'Connell A, Finn G, Raje N December 12, 2022 ASH 2022 Hematology

MagnetisMM-4: An Open-Label, Phase 1b/2 Umbrella Study of Elranatamab in Combination With Other Anti-Cancer Treatments for Patients With Multiple Myeloma

View Presentation View Abstract Plain Language Summary

Poster

Pennesi E, Brivio E, Pelletier KB, Chen Y, Huitema ADR, Jiang Y, Ammerlaan ACJ, Sleight B, Locatelli F, van der Sluis IM, Rossig C, Chen-Santel C, Bielorai B, Petit A, Starý J, Sramkova L, Díaz-de-Heredia C, Rives S, O'Marcaigh A, Rizzari C, Engstler G, Nysom K, Rubio-San-Simón A, Sirvent FJB, Bruno B, Bertrand Y, Brethon B, Rialland F, Plat G, Dirksen U, Garrett M, Zwaan CM December 12, 2022 ASH 2022 Hematology

Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) as Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia – Results From the ITCC-059 Phase IA and Phase II Trial

View Presentation

Poster

Li J, Hibma JE, O’Gorman M, McCush F, Kirkovsky L, Chen Y March 24, 2023 ASCPT 2023 Hematology

Characterization of Gemtuzumab Ozogamicin Pharmacokinetics in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Fractionated Dosing Regimen

View Presentation

Poster

Rashid J, Hibma JE, Benner RJ, Bousset P, Vandendries ER, Chen Y March 24, 2023 ASCPT 2023 Hematology

Concentration-QT Modeling Analysis of Gemtuzumab Ozogamicin Following Fractionated Dosing Regimen in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia

View Presentation

Poster

Costa LJ, LeBlanc TW, Tesch H, Sonneveld P, Kyle R, Sinyavskaya L, Hlavacek P, Meche A, Ren J, Schepart A, Aydin D, DiBonaventura M June 3, 2023 ASCO 2023 Hematology

An Indirect Comparison of Elranatamab’s (ELRA) Objective Response Rate (ORR) From MagnetisMM-3 (MM-3) vs Real-World External Control Arms in Triple-Class Refractory (TCR) Multiple Myeloma (MM)

View Presentation View Abstract Plain Language Summary

Oral Presentation

Nooka AK, Lesokhin AM, Mohty M, Niesvizky R, Maisel C, Arnulf B, Larson SM, Varshavsky-Yanovsky AN, Leleu X, Karlin L, Vesole DH, Bahlis NJ, de Larrea CF, Raje N, Leip E, Conte U, Elmeliegy M, Viqueira A, Manier S June 3, 2023 ASCO 2023 Hematology

Efficacy and Safety of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma and Prior B-cell Maturation Antigen (BCMA)-Directed Therapies: A Pooled Analysis From MagnetisMM Studies

View Presentation View Abstract Plain Language Summary

Poster

Raje N, Leleu X, Lesokhin A, Mohty M, Nooka AK, Leip E, Conte U, Viqueira A, Manier S June 5, 2023 ASCO 2023 Hematology

Efficacy and Safety of Elranatamab by Age and Frailty in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM): A Subgroup Analysis From MagnetisMM-3

View Presentation View Abstract Plain Language Summary

Poster

Mohty M, Tomasson MH, Arnulf B, Bahlis NJ, Prince HM, Niesvizky R, Rodrίguez-Otero P, Martinez-Lopez J, Koehne G, Jethava Y, Gabayan AE, Stevens DA, Nooka AK, Raje N, Iida S, Leip E, Conte U, Czibere A, Viqueira A, Lesokhin AM June 5, 2023 ASCO 2023 Hematology

Elranatamab, a B-cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, for Patients With Relapsed/Refractory Multiple Myeloma: Extended Follow-Up and Biweekly Administration From the MagnetisMM-3 Study

View Presentation View Abstract Plain Language Summary

Poster

Bahlis NJ, Quach H, Weisel K, Viqueira A, Wang S-W, Hamilton PT, Xie T, O’Brien T, Rodriguez-Otero P June 5, 2023 ASCO 2023 Hematology

Genomic Analysis to Identify Determinants of Inherent Response and Resistance to Elranatamab in MagnetisMM-3 Cohort A

View Presentation View Abstract Plain Language Summary